secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001628280-25-028820
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion shareholders approve 6.25M share increase to 2022 stock plan
---------------------------------------------------------------------

- Shareholders approved amendment to 2022 Stock Option and Incentive Plan, increasing authorized shares by 6,250,000.
- Class III directors Jay P. Shepard (75.8M for) and Seth H.Z. Fischer (83.3M for) elected to board until 2028.
- Advisory vote on executive compensation passed with 70.8M for, 26.7M against, 1.5M abstain.
- Ratification of Ernst & Young as independent auditor for FY2025 approved: 118.2M for, 16.1M against.
- Shares outstanding as of record date: 198,149,421; quorum of 136,468,661 shares present.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025028820/0001628280-25-028820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025028820/espr-20250529.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-028820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer